Back

Does the length of evolocumab use contribute to myocardial infarction associated hospital readmissions in patients with ACS?: a single center real world evidence from ELAINE

4 April 2025 (10:00 - 10:45)
Organised by: Logo
Congress Presentation Part of: Dyslipidaemia management in 2025: status quo and best practice (1) Prevention EAPC Premium Access ESC Preventive Cardiology 2025 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Doctor Omar Wani

Northern Arizona Healthcare, Flagstaff (United States of America)

4 More presentations in this session

Presentation thumbnail
Statin intolerance in a real word setting of Italian cardiology centers: data from the BRING-UP Prevention study
Doctor S. Di Fusco (Rome, IT)
Abstract Slides
Presentation thumbnail
Deficient perceptions and practices concerning elevated lipoprotein(a) among specialists in Singapore
Doctor W. Loh (Singapore, SG)
Abstract Slides
Presentation thumbnail
The prevalence and accumulation of main cardiometabolic risk factors among the finnish adult population at different levels of lp(a)
Professor P. Jousilahti (Helsinki, FI)
Abstract Slides
Presentation thumbnail
A collaborative working project in primary care: optimising lipid lowering therapies for secondary prevention in high risk patients
Doctor J. Ward (Westbury, GB)
Abstract Slides

Access the full session

Session thumbnail
Dyslipidaemia management in 2025: status quo and best practice (1)

The Event

Event poster

ESC Preventive Cardiology 2025

4 April 2025 10:00 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources